Economic Implications of Current Age-Related Macular Degeneration Treatments

Ophthalmology

Volumn 116, Issue 3, 2009, Pages 481-487

  Smiddy, William E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VERTEPORFIN;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DRUG COST; HEALTH CARE COST; HUMAN; MEDICAL PRACTICE; MEDICARE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REIMBURSEMENT; RETINA MACULA AGE RELATED DEGENERATION; STATISTICAL MODEL; UNITED STATES; UNIVERSITY HOSPITAL;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HEALTH CARE COSTS; HUMANS; MACULAR DEGENERATION; MODELS, ECONOMIC; PHOTOCHEMOTHERAPY; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION DISORDERS; VISUAL ACUITY;

EID: 61349102385     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.10.029     Document Type: Article

References (40)

1. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
2. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
3. Regillo C.D., Brown D.M., Abraham P., et al., PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145 (2008) 239-248
4. Fung A.E., Lalwani G.A., Rosenfeld P.J., et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143 (2007) 566-583
5. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
6. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
7. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
8. Emerson M.V., Lauer A.K., Flaxel C.J., et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27 (2007) 439-444
9. Bashshur Z.F., Haddad Z.A., Schakal A., et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145 (2008) 249-256
10. Augustin A.J., Puls S., and Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 27 (2007) 133-140
11. Dhalla M.S., Shah G.K., Blinder K.J., et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 26 (2006) 988-993
12. Heier J.S., Boyer D.S., Ciulla T.A., et al., FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 124 (2006) 1532-1542
13. Antoszyk A.N., Tuomi L., Cung C.Y., Singh A., and FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145 (2008) 862-874
14. Husain D., Kim I., Gauthier D., et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123 (2005) 509-516
15. Lazic R., and Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114 (2007) 1179-1185
16. Smith B.T., Dhalla M.S., Shah G.K., et al. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 28 (2008) 675-681
17. Ciulla T. Targeting VEGF: The vEGF trap clinical trials. http://www.revophth.com/index.asp?page=1_13637.htm Accessed October 23, 2008
18. Reich S.J., Fosnot J., Kuroki A., et al. Small interfering RNA (siRNAs) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9 (2003) 210-216
19. Smiddy W.E. Relative cost of a line of vision in age-related macular degeneration. Ophthalmology 114 (2007) 847-854
20. FCSO's Florida Medicare Provider Web Site. 2007 Revised FL Fee Schedule LOC 04-12/20/2006. Locality 04; 2007 Physician and Nonphysician Practitioner Fee [file]. http://www.floridamedicare.com/Part_B/Fee_Schedules/Files/index.asp Accessed August 8, 2008
21. Kaiser P.K., and Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension. TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1132-1142
22. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 117 (1999) 1329-1345
23. Social Security Online. Statistical Tables. Period Live Table (2004). http://www.ssa.gov/OACT/STATS/table4c6.html Accessed October 16, 2008
24. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 131 (2001) 541-560
25. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
26. Wong T.Y., Chakravarthy U., Klein R., et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature. Ophthalmology 115 (2008) 116-126
27. Spaide R.F., Sorenson J., and Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112 (2005) 301-304
28. Spaide R.F., Sorenson J., and Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 25 (2005) 685-690
29. Augustin A.J., and Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 141 (2006) 638-645
30. Antoszyk A.N., Tuomi L., Chung C.Y., Singh A., and FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145 (2008) 862-874
31. Current Controlled Trials. Trial Registration. VERITAS: a safety and efficacy study comparing the combination treatments of verteporfin therapy plus one of two different doses of intravitreal triamcinolone acetonide and the verteporfin therapy plus intravitreal pegaptanib. http://www.controlled-trials.com/mrct/trial/434785/veritas Accessed August 8, 2008
32. Costa R.A., Jorge R., Calucci D., et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 245 (2007) 1273-1280
33. Gupta O.P., Brown G.C., and Brown M.M. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery. Am J Ophthalmol 145 (2008) 923-928
34. Brown M.M., Brown G.C., Brown H.C., et al. The comparative effectiveness and cost-effectiveness of vitreoretinal interventions. Curr Opin Ophthalmol 19 (2008) 202-207
35. Brown M.M., Brown G.C., Brown H.C., and Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 115 (2008) 1039-1045
36. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 143 (2007) 679-680
37. Klein R.M., and Klein R.B. Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration. Retina 27 (2007) 1163-1165
38. Rosenfeld P.J. Intravitareal Avastin: the low cost alternative to Lucentis?. Am J Ophthalmol (2006) 141-143
39. Spaide R.F. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 141 (2006) 149-156
40. Heier J.S. Positive primary endpoint results reported in phase 2 VEGF Trap-EYE. The Ophthalmology Report 1 (2007) 5-11